Cargando…

Nomen est Omen: do antidepressants increase p11 or S100A10?

Occasionally, multiple names are given to the same gene/protein. When this happens, different names can be used in subsequent publications, for example in different research areas, sometimes with little or no awareness that the same entity known under a different name may have a major role in anothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Manev, Hari, Manev, Radmila
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481606/
https://www.ncbi.nlm.nih.gov/pubmed/16722532
http://dx.doi.org/10.1186/1747-5333-1-5
_version_ 1782128274813485056
author Manev, Hari
Manev, Radmila
author_facet Manev, Hari
Manev, Radmila
author_sort Manev, Hari
collection PubMed
description Occasionally, multiple names are given to the same gene/protein. When this happens, different names can be used in subsequent publications, for example in different research areas, sometimes with little or no awareness that the same entity known under a different name may have a major role in another field of science. Recent reports about the protein p11 presented findings that this protein, commonly known as S100A10, may play a crucial role in depression and antidepressant treatment mechanisms. One set of data showed an increased expression of this protein in the brain of mice treated with antidepressants. P11/S100A10 is only one of several S100 proteins expressed in the brain. Interestingly, it has been previously noted that antidepressant treatment increases the brain content of another S100 protein, S100B. It appears that up-regulating the brain content of various S100 proteins might be a common feature of antidepressants. In cells coexpressing S100A10 and S100B, these proteins may interact and exert opposite regulatory roles. Nevertheless, S100A10 is predominantly expressed in certain types of neurons whereas S100B is more abundant in glia. Thus, an interplay among multiple members of the S100 proteins might be important in determining the region and cell specificity of antidepressant mechanisms. Calling the p11 protein by its other name, S100A10, may prompt more investigators from different fields to participate in this new direction of neurobiological research.
format Text
id pubmed-1481606
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14816062006-06-22 Nomen est Omen: do antidepressants increase p11 or S100A10? Manev, Hari Manev, Radmila J Biomed Discov Collab Focus Occasionally, multiple names are given to the same gene/protein. When this happens, different names can be used in subsequent publications, for example in different research areas, sometimes with little or no awareness that the same entity known under a different name may have a major role in another field of science. Recent reports about the protein p11 presented findings that this protein, commonly known as S100A10, may play a crucial role in depression and antidepressant treatment mechanisms. One set of data showed an increased expression of this protein in the brain of mice treated with antidepressants. P11/S100A10 is only one of several S100 proteins expressed in the brain. Interestingly, it has been previously noted that antidepressant treatment increases the brain content of another S100 protein, S100B. It appears that up-regulating the brain content of various S100 proteins might be a common feature of antidepressants. In cells coexpressing S100A10 and S100B, these proteins may interact and exert opposite regulatory roles. Nevertheless, S100A10 is predominantly expressed in certain types of neurons whereas S100B is more abundant in glia. Thus, an interplay among multiple members of the S100 proteins might be important in determining the region and cell specificity of antidepressant mechanisms. Calling the p11 protein by its other name, S100A10, may prompt more investigators from different fields to participate in this new direction of neurobiological research. BioMed Central 2006-04-13 /pmc/articles/PMC1481606/ /pubmed/16722532 http://dx.doi.org/10.1186/1747-5333-1-5 Text en Copyright © 2006 Manev and Manev; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Focus
Manev, Hari
Manev, Radmila
Nomen est Omen: do antidepressants increase p11 or S100A10?
title Nomen est Omen: do antidepressants increase p11 or S100A10?
title_full Nomen est Omen: do antidepressants increase p11 or S100A10?
title_fullStr Nomen est Omen: do antidepressants increase p11 or S100A10?
title_full_unstemmed Nomen est Omen: do antidepressants increase p11 or S100A10?
title_short Nomen est Omen: do antidepressants increase p11 or S100A10?
title_sort nomen est omen: do antidepressants increase p11 or s100a10?
topic Focus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481606/
https://www.ncbi.nlm.nih.gov/pubmed/16722532
http://dx.doi.org/10.1186/1747-5333-1-5
work_keys_str_mv AT manevhari nomenestomendoantidepressantsincreasep11ors100a10
AT manevradmila nomenestomendoantidepressantsincreasep11ors100a10